SCHEMBL6983665

SCHEMBL6983665

CC(C)C(C)(C)OC(N)=O

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.33
TSHR P16473 3/20 0.33
CHRM2 P08172 1/20 0.33
CHRM4 P08173 1/20 0.33
CHRM5 P08912 1/20 0.33
CHRM1 P11229 1/20 0.33
CHRM3 P20309 1/20 0.33
CYP2C9 P11712 1/20 0.33
MAPT P10636 1/20 0.32
HSD17B10 Q99714 1/20 0.32
ALOX15 P16050 2/20 0.32
ATM Q13315 1/20 0.31
CHRNB2 P17787 1/20 0.31
CHRNB4 P30926 1/20 0.31
CHRNA3 P32297 1/20 0.31
CHRNA4 P43681 1/20 0.31
CYP3A4 P08684 1/20 0.31
NFKB1 P19838 1/20 0.31
ADRA1A P35348 1/20 0.31
RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8853469 0.82 CHRM2 (0.30) LMNATSHRCHRM2CHRM4CHRM5
SCHEMBL6043728 0.82 CHRM2 (0.30) LMNATSHRCHRM2CHRM4CHRM5
SCHEMBL28264411 0.82 CHRM2 (0.30) LMNATSHRCHRM2CHRM4CHRM5
SCHEMBL110853 0.79 LMNA (0.30) LMNAHSD17B10
SCHEMBL15685824 0.79 LMNA (0.30) LMNAHSD17B10
SCHEMBL27477536 0.79 ALOX15 (0.36) LMNATSHRCHRM2CHRM4CHRM5
SCHEMBL19865074 0.79 LMNA (0.32) LMNATSHRCHRM2CHRM4CHRM5
SCHEMBL27783021 0.79
SCHEMBL11001316 0.78 CTSK (0.34) LMNATSHRCHRM2CHRM4CHRM5
SCHEMBL28224248 0.77 DPP4 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106920694-A Conductive material and capacitor 财团法人工业技术研究院 2017-07-04 CN claimed
US-12494326-B2 Composition for electrolytic capacitor and electrolytic capacitor including the same INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2025-12-09 US disclosed
US-20230107749-A1 COMPOSITION FOR ELECTROLYTIC CAPACITOR AND ELECTROLYTIC CAPACITOR INCLUDING THE SAME INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2023-04-06 US disclosed
CN-113527186-A Asymmetric catalytic synthesis method of chiral alpha-azaarene tertiary carbon center compound 河南工业大学 2021-10-22 CN disclosed
EP-3564238-B1 FUSED HETEROCYCLIC COMPOUND HAVING OXIME GROUP OR SALTS THEREOF, AGRICULTURAL/HORTICULTURAL INSECTICIDE CONTAINING SAID COMPOUNDS, AND METHOD FOR USING SAID INSECTICIDE NIHON NOHYAKU CO LTD (JP) 2021-10-13 EP disclosed
CN-110797199-B Conductive polymer composite material and capacitor 财团法人工业技术研究院 2021-06-18 CN disclosed
US-10856548-B2 Oxime group-containing condensed heterocyclic compound or salt thereof, agricultural and horticultural insecticide comprising the compound or the salt, and method for using the insecticide NIHON NOHYAKU CO., LTD. (JP) 2020-12-08 US disclosed
US-10790072-B2 Conductive polymer composite material and capacitor INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2020-09-29 US disclosed
US-20200085054-A1 OXIME GROUP-CONTAINING CONDENSED HETEROCYCLIC COMPOUND OR SALT THEREOF, AGRICULTURAL AND HORTICULTURAL INSECTICIDE COMPRISING THE COMPOUND OR THE SALT, AND METHOD FOR USING THE INSECTICIDE NIHON NOHYAKU CO., LTD. (JP) 2020-03-19 US disclosed
CN-110797199-A Conductive polymer composite material and capacitor 财团法人工业技术研究院 2020-02-14 CN disclosed
CN-104781424-B The MIR-18B of the therapeutic targets of marker and treating cancer as cancer progression 萨特西湾医院 2018-11-23 CN disclosed
US-9221771-B2 Method for the preparation of substituted oxazolidinones SANDOZ AG (CH) 2015-12-29 US disclosed
EP-2697209-B1 METHOD FOR THE PREPARATION OF SUBSTITUTED OXAZOLIDINONES SANDOZ AG (CH) 2015-09-23 EP disclosed
US-20140213784-A1 METHOD FOR THE PREPARATION OF SUBSTITUTED OXAZOLIDINONES SANDOZ AG (CH) 2014-07-31 US disclosed
EP-2697209-A1 METHOD FOR THE PREPARATION OF SUBSTITUTED OXAZOLIDINONES Sandoz AG (CH) 2014-02-19 EP disclosed
WO-2012140061-A1 METHOD FOR THE PREPARATION OF SUBSTITUTED OXAZOLIDINONES SANDOZ AG (CH) 2012-10-18 WO disclosed
WO-2011108744-A1 ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, AND RESIST FILM AND PATTERN FORMING METHOD USING THE SAME FUJIFILM CORPORATION (JP) 2011-09-09 WO disclosed
EP-0934938-B1 SUBSTITUTED BENZOYLAMINOTHIAZOLE DERIVATIVES AND DRUGS CONTAINING THE SAME ZERIA PHARM CO LTD (JP) 2003-01-15 EP disclosed
US-6121301-A ADMINISTERING TO PREVENT OR TREAT GASTROINTESTINAL DYSMOTILITY; COMPOUNDS SUCH AS 2-((N-(3-CYANOBENZOYL)AMINO)-4-((3-DIISOPROPYLAMINOPROPYL)AMINOCARBONYL)-1,3-THIAZOLE ZERIA PHARMACEUTICAL CO., LTD. (JP) 2000-09-19 US disclosed
EP-0934938-A1 SUBSTITUTED BENZOYLAMINOTHIAZOLE DERIVATIVES AND DRUGS CONTAINING THE SAME ZERIA PHARMACEUTICAL CO., LTD. (JP) 1999-08-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200085054-A1 OXIME GROUP-CONTAINING CONDENSED HETEROCYCLIC COMPOUND OR SALT THEREOF, AGRICULTURAL AND HORTICULTURAL INSECTICIDE COMPRISING THE COMPOUND OR THE SALT, AND METHOD FOR USING THE INSECTICIDE OXSR1, CBR3, OSR1 LMNA 3180/4885TSHR 1347/4885CHRM2 194/4885
US-10856548-B2 Oxime group-containing condensed heterocyclic compound or salt thereof, agricultural and horticultural insecticide comprising the compound or the salt, and method for using the insecticide OXSR1, CBR3, OSR1 LMNA 3180/4885TSHR 1347/4885CHRM2 194/4885
US-20140213784-A1 METHOD FOR THE PREPARATION OF SUBSTITUTED OXAZOLIDINONES OXA1L, XDH, AOX1 LMNA 2033/4885TSHR 3893/4885CHRM2 4272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.